Delving into the Latest Updates on Codrituzumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

+ [2]

Target

GPC3

Mechanism

GPC3 inhibitors(Glypican-3 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Antibody-dependent cellular phagocytosis (ADCP) effects

Therapeutic Areas

Neoplasms

Active Indication

GPC3 Positive NeoplasmsSolid tumor

Inactive Indication

Metastatic hepatocellular carcinoma

Originator Organization

Chugai Pharmaceutical Co., Ltd.

Active Organization

Chugai Pharma USA LLC

Inactive Organization

Hoffmann-La Roche, Inc.

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Gene Sequence

Sequence Code 13592L

Source: *****

Sequence Code 13574H

Source: *****

The purpose of this study to find out whether codrituzumab is a safe treatment that causes few or mild side effects in children and young adults who have solid tumors that express the protein GPC3. The researchers also want to study the way codrituzumab is absorbed, distributed, and cleared from the body.

Start Date09 Jun 2021

Sponsor / Collaborator

Memorial Sloan Kettering Cancer Center

[+1]

JPRN-JapicCTI-163325 / CompletedPhase 1

A PHASE I, OPEN-LABEL, MULTI-CENTER, DOSE-ESCALATION STUDY OF CODRITUZUMAB, AN ANTI-GLYPICAN-3 MONOCLONAL ANTIBODY, IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA

Start Date01 Aug 2016

Sponsor / Collaborator

Chugai Pharmaceutical Co., Ltd.

EUCTR2011-003574-84-DE / Not yet recruitingPhase 2

A Randomized, Placebo-controlled, Double-blind,Multicenter Phase II Trial of Intravenous GC33 at 1600 mgQ2W in Previously Treated Patients with UnresectableAdvanced or Metastatic Hepatocellular Carcinoma (HCC).

Start Date15 May 2012

Sponsor / Collaborator

F. Hoffmann-La Roche Ltd.

100 Clinical Results associated with Codrituzumab

Login to view more data

100 Translational Medicine associated with Codrituzumab

Login to view more data

100 Patents (Medical) associated with Codrituzumab

Login to view more data

21

Literatures (Medical) associated with Codrituzumab

01 Oct 2023·Molecular Immunology

A novel bispecific antibody as an immunotherapeutic agent in hepatocellular carcinoma

Article

Author: Song, Qifeng ; Zhao, Liwen ; Luo, Cheng ; Wang, Yong ; Wei, Jian ; Xu, Yao ; Liu, Qingxia

Hepatocellular carcinoma (HCC) remains one of the most common and highly fatal malignancies in humans worldwide with increasing prevalence and limited therapeutic options. For many decades, many researchers have attempted to find effective curative methods for HCC and great strides have been made. GPC3 is overexpressed in HCC, but not in normal liver, making it a rational immunotherapeutic target for HCC. GC33, a humanized mAb directed against GPC3, is a safe and well-tolerated therapy choice for patients with HCC, which tested in a phase I trial in advanced HCC patients. Phase II trials of GC33 to evaluate its efficacy and safety in advanced or metastatic HCC, showed no significant differences in overall survival and progression-free survival compared with the placebo. Retrospective analysis indicates that high drug exposure and high CD16 expression may contribute to the clinical efficacy of GC33. Chugai Pharmaceutical has restarted its Phase I trial of GC33, continuing to explore its clinical value targeting GPC3 in solid tumors. To enhance the antitumor potency of GC33, we designed a GPC3/CD16A bispecific antibody (QDEB). In this study, we obtained QDEB at high purity and assessed its effectiveness in the therapy of HCC compared with GC33. In vitro cytotoxicity assays and in vivo experiments demonstrated that QDEB could enhance anti-tumor efficacy compared with GC33. CD16A activation and increased cytokines release were associated with higher anti-tumor activity. In conclusion, this bispecific antibody may possibly help develop new therapeutic strategies for HCC and develop new treatment options in the future.

01 Aug 2022·Hepatology

Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC

Article

Author: Peng, Yibing ; He, Yukai ; Caraballo Galva, Leidy D ; He, Aiwu Ruth ; Mao, Rui ; Shi, Huidong ; Zhang, Huajun ; Jiang, Xiaotao ; Qiu, Xiangguo ; Sadek, Ramses ; Brody, Pierce ; Hussein, Mohamed S ; Kehinde-Ige, Mercy

AbstractBackground and AimsChimeric antigen receptor engineered T cells (CARTs) for HCC and other solid tumors are not as effective as they are for blood cancers. CARTs may lose function inside tumors due to persistent antigen engagement. The aims of this study are to develop low‐affinity monoclonal antibodies (mAbs) and low‐avidity CARTs for HCC and to test the hypothesis that low‐avidity CARTs can resist exhaustion and maintain functions in solid tumors, generating durable antitumor effects.Methods and ResultsNew human glypican‐3 (hGPC3) mAbs were developed from immunized mice. We obtained three hGPC3‐specific mAbs that stained HCC tumors, but not the adjacent normal liver tissues. One of them, 8F8, bound an epitope close to that of GC33, the frequently used high‐affinity mAb, but with approximately 17‐fold lower affinity. We then compared the 8F8 CARTs to GC33 CARTs for their in vitro function and in vivo antitumor effects. In vitro, low‐avidity 8F8 CARTs killed both hGPC3high and hGPC3low HCC tumor cells to the same extent as high‐avidity GC33 CARTs. 8F8 CARTs expanded and persisted to a greater extent than GC33 CARTs, resulting in durable responses against HCC xenografts. Importantly, compared with GC33 CARTs, there were 5‐fold more of 8F8‐BBz CARTs in the tumor mass for a longer period of time. Remarkably, the tumor‐infiltrating 8F8 CARTs were less exhausted and apoptotic, and more functional than GC33 CARTs.ConclusionThe low‐avidity 8F8‐BBz CART resists exhaustion and apoptosis inside tumor lesions, demonstrating a greater therapeutic potential than high‐avidity CARTs.

01 Dec 2020·Cancer Biology & TherapyQ3 · MEDICINE

Heparan sulfate proteoglycans as targets for cancer therapy: a review

Q3 · MEDICINE

Review

Author: Ferreira, Bianca Zaia Franco ; Lopes, Carla Cristina ; Onyeisi, Jessica Oyie Sousa ; Nader, Helena Bonciani

Heparan sulfate proteoglycans (HSPGs) play important roles in cancer initiation and progression, by interacting with the signaling pathways that affect proliferation, adhesion, invasion and angiogenesis. These roles suggest the possibility of various strategies of regulation of these molecules. In this review, we demonstrated that the anticancer drugs can regulate the heparan sulfate proteoglycans activity in different ways: some act directly in core protein, and can bind to a specific type of HSPG. Others drugs interact with glycosaminoglycans chains, and others can act directly in enzymes that regulate HSPGs levels. We also demonstrated that the HSPGs drug targets can be divided into four groups: monoclonal antibodies, antitumor antibiotic, natural products, and mimetics peptide. Interestingly, many drugs demonstrated in this review are approved by FDA and is used in cancer therapy (Food and Drug Administration) like trastuzumab, panitumumab, bleomycin and bisphosphonate zoledronic acid (ASCO) or are in clinical trials like codrituzumab and genistein. This review should help researchers to understand the mechanism of action of anticancer drugs existing and also may inspire the discovery of new drugs that regulate the heparan sulfate proteoglycans activity.

100 Deals associated with Codrituzumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14843

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic hepatocellular carcinoma	Preclinical	HK	Hoffmann-La Roche, Inc.	02 Feb 2012
Metastatic hepatocellular carcinoma	Preclinical	JP	Hoffmann-La Roche, Inc.	02 Feb 2012
Metastatic hepatocellular carcinoma	Preclinical	SG	Hoffmann-La Roche, Inc.	02 Feb 2012
Metastatic hepatocellular carcinoma	Preclinical	TW	Hoffmann-La Roche, Inc.	02 Feb 2012
Metastatic hepatocellular carcinoma	Preclinical	NZ	Hoffmann-La Roche, Inc.	02 Feb 2012
Metastatic hepatocellular carcinoma	Preclinical	BE	Hoffmann-La Roche, Inc.	02 Feb 2012
Metastatic hepatocellular carcinoma	Preclinical	KR	Hoffmann-La Roche, Inc.	02 Feb 2012
Metastatic hepatocellular carcinoma	Preclinical	IT	Hoffmann-La Roche, Inc.	02 Feb 2012
Metastatic hepatocellular carcinoma	Preclinical	GB	Hoffmann-La Roche, Inc.	02 Feb 2012
Metastatic hepatocellular carcinoma	Preclinical	DE	Hoffmann-La Roche, Inc.	02 Feb 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


JPRN-JapicCTI-163325 (ESMO2018)	Phase 1	Metastatic hepatocellular carcinoma	20	Codrituzumab 1600mg	(zntnbsguht) = 0% vs 15% vs 0% dyzjbizydf (wyzxevtbwj ) View more	Positive	21 Oct 2018
				Atezolizumab 1200mg
NCT01507168 (Pubmed \| J Hepatol) Manual	Phase 2	Advanced Hepatocellular Carcinoma	185	codrituzumab	(nhjwgeikla) = gklrcypiej qefrbgfcjj (vewzqjtgqd ) View more	Negative	01 Aug 2016
				Placebo	(nhjwgeikla) = rlimoghjqi qefrbgfcjj (vewzqjtgqd ) View more
NCT01507168 (ASCO2014)	Phase 2	Unresectable Hepatocellular Carcinoma	185	GC33 1600 mg	(asjdqtbwjf) = ttjuuimuxz petfzoetma (bjjcrrnewt ) View more	-	20 May 2014
				Placebo	(asjdqtbwjf) = mvcpieehud petfzoetma (bjjcrrnewt ) View more